pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
DAIICHI SANKYO · news · pharmadog
← back to DAIICHI SANKYO
News mentioning DAIICHI SANKYO
36
stories
May 11, 26
Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
endpoints
May 8, 26
Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
onclive
May 8, 26
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
onclive
May 8, 26
Daiichi Sankyo posts 'extraordinary loss' of nearly $1B
endpoints
May 5, 26
Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
onclive
Apr 24, 26
Daiichi Sankyo postpones annual results, stock dips
endpoints
← prev
page 2 of 2
next →
